Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: A multicentre phase II study

Andrew M. Evens, Mitchell R. Smith, Izidore S. Lossos, Irene Helenowski, Michael Millenson, Jane N. Winter, Steve T. Rosen, Leo I. Gordon

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: A multicentre phase II study'. Together they form a unique fingerprint.

Medicine & Life Sciences